Intelligence Platform

Patents

Browse 166 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10005834

Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10001483

Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulat

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9925271

Targeted pharmacological chaperones

Marker Gene Technologies, Inc · Granted Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9850313

Cancer biomarkers and methods of use thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Dec 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9846160

Ganglioside GD2 as a marker and target on cancer stem cells

The Board of Regents of the University of Texas System · Granted Tue Dec 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9841426

Intracellular organelle peptide targeted enzyme substrates

Marker Gene Technologies, Inc · Granted Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9828634

Markers for differentiation of stem cells into differentiated cell populations

REGENERATIVE MEDICAL SOLUTIONS, INC. · Granted Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9804163

Biomarkers for prostate cancer and methods for their detection

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9783855

Cancer screening by detection of ultrastructural and molecular markers

Northwestern University · Granted Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9732386

Cell aging as a unique biomarker of major depression

The Regents of the University of California · Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9730954

miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of dr

The Board of Regents of the University of Texas System · Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9719144

Microbiome markers and therapies for autism spectrum disorders

THE ARIZONA BOARD OF REGENTS · Granted Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9702007

Genetic markers predictive of response to glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9687522

Methods of treating a subject afflicted with an autoimmune disease using predictive biomar

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9682132

Compositions and methods relating to argininosucccinate synthetase

BANYAN BIOMARKERS, INC. · Granted Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9651562

Cathelicidin as novel inflammatory bowel disease marker and therapy for colitis associated

The Regents of the University of California · Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9625473

Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9617596

Biomarkers predictive for clinical response for glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9610358

Targeted pharmacological chaperones

Marker Gene Technologies, Inc · Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9512401

B and T lymphocyte attenuator marker for use in adoptive T-cell therapy

The Board of Regents of the University of Texas System · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9452182

Collateral gene inactivation biomarkers and targets for cancer therapy

The Board of Regents of the University of Texas System · Granted Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9278124

Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and co

HALOZYME, INC. · Granted Tue Mar 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9180179

Development of a marker foot and mouth disease virus vaccine candidate that is attenuated

The United States of America, as represented by the Secretary of Agriculture · Granted Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9176122

Biomarkers for predicting response to immunosuppressive therapy

United States Department of Veteran Affairs · Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted